As WBC's It!

IMS Health data for 2009 creates an interesting picture of global drug sales and growth in specific therapeutic classes. WBC has taken a look and found that the global pictureis clearly different when compared to  U.S. pharmacy benefit plan sponsor drug spend.  In the U.S., antipsychotics were the leading therapeutic class with $14.6 billion in sales. (more)

Specialty Drug Management

Sometimes referred to as biologics, specialty drugs continues to represent one of the most significant components in a plan sponsor's overall drug spend. By definition, these drugs require special handling, many times administered by infusion or injection, and are very high cost. While today, most specialty treatments are prescribed for relatively rare conditions ( MS, rheumatoid arthritis, hemophilia, etc.) and cancer, the next few years will see the treatment of chronic conditions, such as diabetes and heart disease, with specialty drugs. A well-designed specialty drug strategy is necessary to help mitigate these rising costs. WBC is at the forefront of designing these strategies. Click to learn more.